Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where B.G. Muller is active.

Publication


Featured researches published by B.G. Muller.


BMJ Open | 2014

The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol

W. van den Bos; D. M. de Bruin; B.G. Muller; Ioannis Varkarakis; A.A. Karagiannis; Patricia J. Zondervan; M.P. Laguna Pes; Denise P. Veelo; C D Savci Heijink; Marc R. Engelbrecht; Hessel Wijkstra; T.M. De Reijke; J.J.M.C.H. de la Rosette

Introduction Current surgical and ablative treatment options for prostate cancer have a relatively high incidence of side effects, which may diminish the quality of life. The side effects are a consequence of procedure-related damage of the blood vessels, bowel, urethra or neurovascular bundle. Ablation with irreversible electroporation (IRE) has shown to be effective in destroying tumour cells and harbours the advantage of sparing surrounding tissue and vital structures. The aim of the study is to evaluate the safety and efficacy and to acquire data on patient experience of minimally invasive, transperineally image-guided IRE for the focal ablation of prostate cancer. Methods and analysis In this multicentre pilot study, 16 patients with prostate cancer who are scheduled for a radical prostatectomy will undergo an IRE procedure, approximately 30 days prior to the radical prostatectomy. Data as adverse events, side effects, functional outcomes, pain and quality of life will be collected and patients will be controlled at 1 and 2 weeks post-IRE, 1 day preprostatectomy and postprostatectomy. Prior to the IRE procedure and the radical prostatectomy, all patients will undergo a multiparametric MRI and contrast-enhanced ultrasound of the prostate. The efficacy of ablation will be determined by whole mount histopathological examination, which will be correlated with the imaging of the ablation zone. Ethics and dissemination The protocol is approved by the ethics committee at the coordinating centre (Academic Medical Center (AMC) Amsterdam) and by the local Institutional Review Board at the participating centres. Data will be presented at international conferences and published in peer-reviewed journals. Conclusions This pilot study will determine the safety and efficacy of IRE in the prostate. It will show the radiological and histopathological effects of IRE ablations and it will provide data to construct an accurate treatment planning tool for IRE in prostate tissue. Trial registration number Clinicaltrials.gov database: NCT01790451.


Journal of medical imaging | 2015

Prostate cancer diagnosis: the feasibility of needle-based optical coherence tomography

B.G. Muller; Daniel M. de Bruin; Willemien van den Bos; Martin J. Brandt; Juliëtte F. Velu; Mieke T. J. Bus; Dirk J. Faber; Dilara Savci; Patricia J. Zondervan; Theo M. de Reijke; Pilar Laguna Pes; Jean de la Rosette; Ton G. van Leeuwen

Abstract. The objective of this study is to demonstrate the feasibility of needle-based optical coherence tomography (OCT) and functional analysis of OCT data along the full pullback trajectory of the OCT measurement in the prostate, correlated with pathology. OCT images were recorded using a commercially available C7-XR™ OCT Intravascular Imaging System interfaced to a C7 Dragonfly™ intravascular 0.9-mm-diameter imaging probe. A computer program was constructed for automated image attenuation analysis. First, calibration of the OCT system for both the point spread function and the system roll-off was achieved by measurement of the OCT signal attenuation from an extremely weakly scattering medium (Intralipid® 0.0005 volume%). Second, the data were arranged in 31 radial wedges (pie slices) per circular segments consisting of 16 A-scans per wedge and 5 axial B-scans, resulting in an average A-scan per wedge. Third, the decay of the OCT signal is analyzed over 50 pixels (500  μm) in depth, starting from the first found maximum data point. Fourth, for visualization, the data were grouped with a corresponding color representing a specific μoct range according to their attenuation coefficient. Finally, the analyses were compared to histopathology. To ensure that each single use sterile imaging probe is comparable to the measurements of the other imaging probes, the probe-to-probe variations were analyzed by measuring attenuation coefficients of 0.03, 6.5, 11.4, 17, and 22.7 volume% Intralipid®. Experiments were repeated five times per probe for four probes. Inter- and intraprobe variation in the measured attenuation of Intralipid samples with scattering properties similar to that of the prostate was <8% of the mean values. Mean attenuation coefficients in the prostate were 3.8  mm−1 for parts of the tissue that were classified as benign (SD: 0.8  mm−1, minimum: 2.2  mm−1, maximum: 8.9  mm−1) and 4.1  mm−1 for parts of tissue that were classified as malignant (SD: 1.2  mm−1, minimum: 2.5  mm−1, maximum: 9.0  mm−1). In benign areas, the tissue looked homogeneous, whereas in malignant areas, small glandular structures were seen. However, not all areas in which a high attenuation coefficient became apparent corresponded to areas of prostate cancer. This paper describes the first in-tissue needle-based OCT imaging and three-dimensional optical attenuation analysis of prostate tissue that indicates a correlation with pathology. Fully automated attenuation coefficient analysis was performed at 1300 nm over the full pullback. Correlation with pathology was achieved by coregistration of three-dimensional (3-D) OCT attenuation maps with 3-D pathology of the prostate. This may contribute to the current challenge of prostate imaging and the rising interest in focal therapy for reduction of side effects occurring with current therapies.


The Journal of Urology | 2016

Histopathological Outcomes after Irreversible Electroporation for Prostate Cancer: Results of an Ablate and Resect Study

W. van den Bos; R. R. Jurhill; D. M. de Bruin; C.D. Savci-Heijink; Arnoud W. Postema; Peter G. K. Wagstaff; B.G. Muller; Ioannis Varkarakis; Andreas Skolarikos; Patricia J. Zondervan; M.P. Laguna Pes; T.M. De Reijke; J.J.M.C.H. de la Rosette

PURPOSE Irreversible electroporation is a tissue ablation modality that uses high voltage electric energy to induce an increase in cell membrane permeability. This causes destabilization of the existing cellular transmembrane potential leading to cell death, due to the inability to maintain cellular homeostasis. This phase I-II study was designed to evaluate the histopathological outcomes of irreversible electroporation to prostate and surrounding tissue in radical prostatectomy specimens. MATERIALS AND METHODS Sixteen patients with prostate cancer underwent an irreversible electroporation ablation without curative intent, followed by radical prostatectomy scheduled 4 weeks later. For histopathological examination of the prostate, whole mounted tissue slices were examined by dedicated genitourinary pathologists. The borders of the ablation zone and residual tumor were outlined on the slides. RESULTS The irreversible electroporation ablation zones were characterized as areas of fibrosis, necrosis and loss of epithelial tissue in terms of denudation in the glandular structures. The ablation zone was well demarcated, showing trenchant delineations between viable and nonviable tissue. The ablated tissue showed mild to moderate inflammation, with atrophic cells in 1 case. The area was surrounded by hemorrhage at the location of the electrodes. No skip lesions or viable tissue was seen in the ablation zone. Fibrinoid necrosis of the neurovascular bundle was observed in 13 patients and denudation of the urothelium of the prostatic urethra was seen in 9. CONCLUSIONS Histopathological assessment of the prostate 4 weeks after irreversible electroporation ablation showed sharply demarcated fibrotic and necrotic tissue in the ablation zone. No viable tissue was observed in the irreversible electroporation ablation zone.


Technology in Cancer Research & Treatment | 2017

Customized Tool for the Validation of Optical Coherence Tomography in Differentiation of Prostate Cancer

B.G. Muller; Abel Swaan; D. M. de Bruin; W. van den Bos; A. W. Schreurs; Dirk J. Faber; E. C. H. Zwartkruis; Lawrence Rozendaal; André N. Vis; Jakko A. Nieuwenhuijzen; R. J. A. van Moorselaar; T. G. van Leeuwen; J.J.M.C.H. de la Rosette

Objective: To design and demonstrate a customized tool to generate histologic sections of the prostate that directly correlate with needle-based optical coherence tomography pullback measurements. Materials and Methods: A customized tool was created to hold the prostatectomy specimens during optical coherence tomography measurements and formalin fixation. Using the tool, the prostate could be sliced into slices of 4 mm thickness through the optical coherence tomography measurement trajectory. In this way, whole-mount pathology slides were produced in exactly the same location as the optical coherence tomography measurements were performed. Full 3-dimensional optical coherence tomography pullbacks were fused with the histopathology slides using the 3-dimensional imaging software AMIRA, and images were compared. Results: A radical prostatectomy was performed in a patient (age: 68 years, prostate-specific antigen: 6.0 ng/mL) with Gleason score 3 + 4 = 7 in 2/5 biopsy cores on the left side (15%) and Gleason score 3 + 4 = 7 in 1/5 biopsy cores on the right side (5%). Histopathology after radical prostatectomy showed an anterior located pT2cNx adenocarcinoma (Gleason score 3 + 4 = 7). Histopathological prostate slides were produced using the customized tool for optical coherence tomography measurements, fixation, and slicing of the prostate specimens. These slides correlated exactly with the optical coherence tomography images. Various structures, for example, Gleason 3 + 4 prostate cancer, stroma, healthy glands, and cystic atrophy with septae, could be identified both on optical coherence tomography and on the histopathological prostate slides. Conclusion: We successfully designed and applied a customized tool to process radical prostatectomy specimens to improve the coregistration of whole mount histology sections to fresh tissue optical coherence tomography pullback measurements. This technique will be crucial in validating the results of optical coherence tomography imaging studies with histology and can easily be applied in other solid tissues as well, for example, lung, kidney, breast, and liver. This will help improve the efficacy of optical coherence tomography in cancer detection and staging in solid organs.


Tijdschrift voor Urologie | 2013

7 In vivo optisch coherente tomografie voor evaluatie van hogere urinewegurotheeltumoren – eerste resultaten van een pilotstudie

Mieke T. J. Bus; B.G. Muller; D.M. de Bruin; D.J. Faber; T. G. van Leeuwen; Th.M. De Reijke; J.J.M.C.H. de la Rosette

Tijdschrift voor Urologie mei 2013 nr. 3 Resultaten Zowel na behandeling met op TPCS2a gebaseerde fotodynamische therapie (PDT) alleen, als na behandeling met bleomycine of een van de controlechemotherapeutica alleen werd in alle 5 cellijnen een dosisafhankelijke inhibitie van celproliferatie gezien. Bij de combinatiebehandelingen werd enkel een significant (p < 0,001) synergistisch effect, dus een fotochemisch internalisatie-effect, geobserveerd voor PDT gecombineerd met bleomycine in de T24en de AY-27-cellijn.


Tijdschrift voor Urologie | 2013

11 Van lichtverstrooiing tot Gleason-score: ex-vivo optische coherentietomografie (OCT) van de menselijke prostaat na radicale prostatectomie

B.G. Muller; W. van den Bos; D.M. de Bruin; Martin J. Brandt; D.J. Faber; Patricia J. Zondervan; M.P. Laguna-Pes; T. G. van Leeuwen; J.J.M.C.H. de la Rosette

Materialen en methoden Er zijn 6 naaldgeleide OCT-metingen uitgevoerd in 22 prostaten, direct na radicale prostatectomie. OCT-metingen werden gedaan met een St. Jude intravasculaire OCT-console. Voor het plaatsen van de OCT-probes werden IV-(infuus)naalden gebruikt. De hulzen werden na de meting in het weefsel achtergelaten voor markering van het gemeten traject. Van de ruwe OCTdata werd per locatie de μOCT uitgerekend. Deze μOCT’s werden vergeleken met een 3D-reconstructie van de pathologie. Door middel van ROC-curveanalyse en Mann-Whitney-U-test is het verschil tussen maligne en benigne weefsel geanalyseerd.


World Journal of Urology | 2015

Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project

B.G. Muller; W. van den Bos; Maurizio Brausi; Jurgen J. Fütterer; Sandeep Ghai; Peter A. Pinto; I.V. Popeneciu; T.M. De Reijke; Cary N. Robertson; J.J.M.C.H. de la Rosette; S. Scionti; Baris Turkbey; Hessel Wijkstra; Osamu Ukimura; Thomas J. Polascik


World Journal of Urology | 2016

The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients

W. van den Bos; D. M. de Bruin; R. R. Jurhill; C.D. Savci-Heijink; B.G. Muller; Ioannis Varkarakis; Andreas Skolarikos; Patricia J. Zondervan; M.P. Laguna-Pes; Hessel Wijkstra; T.M. De Reijke; J.J.M.C.H. de la Rosette


European Radiology | 2016

MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy

Willemien van den Bos; D. M. de Bruin; A. van Randen; Marc R. Engelbrecht; Arnoud W. Postema; B.G. Muller; I. M. Varkarakis; A. Skolarikos; C.D. Savci-Heijink; R. R. Jurhill; Patricia J. Zondervan; M.P. Laguna Pes; Hessel Wijkstra; T.M. De Reijke; J.J.M.C.H. de la Rosette


Journal of Biophotonics | 2016

Prostate cancer diagnosis by optical coherence tomography: First results from a needle based optical platform for tissue sampling.

B.G. Muller; Daniel M. de Bruin; Martin J. Brandt; Willemien van den Bos; Suzanne van Huystee; Dirk J. Faber; Dilaria Savci; Patricia J. Zondervan; Theo M. de Reijke; M. Pilar Laguna-Pes; Ton G. van Leeuwen; Jean de la Rosette

Collaboration


Dive into the B.G. Muller's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ioannis Varkarakis

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar

D.J. Faber

Istanbul Technical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge